Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Spray Content Assay Using HPLC – V 2.0

Posted on By

Analytical Method Development: SOP for Spray Content Assay Using HPLC – V 2.0

Standard Operating Procedure for Spray Content Assay Using HPLC in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/246/2025
Supersedes SOP/AMD/246/2022
Page No. Page 1 of 14
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To establish a validated HPLC-based analytical method for quantifying the content of the active pharmaceutical ingredient (API) in individual spray actuations from nasal

or oral sprays to ensure dose uniformity and compliance with regulatory requirements.

2. Scope

This SOP is applicable to Analytical Method Development (AMD) personnel performing quantitative assay of spray content for nasal, buccal, or sublingual metered-dose spray products during formulation development, stability studies, and batch release.

3. Responsibilities

  • Analytical Scientist: Prepares standard and sample solutions, runs HPLC, and calculates assay results.
  • QC Analyst: Assists in spray collection, sample weighing, and documentation.
  • QA Executive: Reviews method suitability and assay results for accuracy and consistency.
See also  Analytical Method Development: pH Method Development for Formulations - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring method validation, data integrity, and compliance with pharmacopeial specifications for spray product assay.

5. Procedure

5.1 Apparatus and Equipment

  1. HPLC system with UV detector
  2. Autosampler, analytical balance (0.1 mg), vortex mixer, sonicator
  3. Volumetric flasks, micropipettes, spray sampling apparatus (e.g., DUSA)

5.2 Chromatographic Conditions (Example)

  1. Column: C18, 150 mm × 4.6 mm, 5 µm
  2. Mobile Phase: 60:40 (v/v) Methanol:Water with 0.1% TFA
  3. Flow Rate: 1.0 mL/min
  4. Detection Wavelength: 220 nm
  5. Injection Volume: 20 µL

5.3 Standard Preparation

  1. Weigh accurately about 25 mg of API reference standard into a 50 mL volumetric flask.
  2. Dissolve in diluent (same as mobile phase) and make up the volume.
  3. Filter through 0.45 µm membrane filter before injection.

5.4 Sample Preparation

  1. Prime the spray device (3 actuations to waste).
  2. Actuate 3 sprays into a 50 mL volumetric flask (or 1 spray per flask for unit dose analysis).
  3. Add diluent, vortex to dissolve content, and sonicate if required.
  4. Make up to volume and filter through 0.45 µm membrane.
See also  Analytical Method Development: SOP for HPTLC Method Development - V 2.0

5.5 System Suitability

  1. Inject standard solution five times.
  2. Ensure % RSD of peak areas ≤ 2.0% and theoretical plates ≥ 2000.

5.6 Assay Calculation

  1. Calculate API content per spray using:

    Spray Content (mg) = (Sample Area / Standard Area) × Standard Concentration × Dilution Factor
  2. Report average content for triplicate sprays and % of label claim.

5.7 Acceptance Criteria

  1. Individual spray content: 85–115% of labeled claim.
  2. RSD for three replicates: ≤ 6.0%.

5.8 Method Validation Requirements

  1. Specificity, Linearity (r ≥ 0.999), Accuracy (98–102%), Precision (% RSD ≤ 2%), Robustness.

6. Abbreviations

  • HPLC: High Performance Liquid Chromatography
  • API: Active Pharmaceutical Ingredient
  • RSD: Relative Standard Deviation
  • DUSA: Dose Uniformity Sampling Apparatus

7. Documents

  1. Spray Assay Data Log – Annexure-1
  2. System Suitability Record – Annexure-2
  3. Spray Assay Validation Report – Annexure-3

8. References

  • USP <601>: Aerosols, Nasal Sprays, and Inhalers
  • ICH Q2(R1): Validation of Analytical Procedures
  • FDA Guidance on Nasal Spray and Inhalation Products

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Deepak Nair Vaidehi Sharma Sunita Reddy
Designation Analytical Chemist QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Spray Assay Data Log

Spray No. Sample Area Calculated Content (mg) % Label Claim Status
1 13456 0.102 102% Pass
2 13289 0.101 101% Pass
3 13110 0.099 99% Pass

Annexure-2: System Suitability Record

Injection Peak Area Retention Time
1 13470 3.58
2 13465 3.59
3 13462 3.58
4 13468 3.58
5 13466 3.59

Annexure-3: Spray Assay Validation Report

The HPLC method for spray content assay was validated as per ICH Q2(R1). Linearity was demonstrated between 50–150% of target concentration (r = 0.9995). Precision (% RSD) was 1.3% and accuracy was within 98.5–101.2%. Method approved for batch release and stability testing.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Added section on system suitability and annexure formatting Annual Review and Enhancement Sunita Reddy
15/02/2022 1.0 Initial Release New SOP QA Head
See also  Analytical Method Development: Integration with Product Development Team - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Temporary SOP Changes Without Change Control: A Hidden Compliance Gap
Next Post: Best Practices for Refresher Training on Critical SOPs

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version